Orphan Synergy Europe - Pharma News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

18.12.24	OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO (GlobeNewswire)
11.12.24	OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® (GlobeNewswire)
02.12.24	OSE Immunotherapeutics Strengthens Leadership and Executive Committee (GlobeNewswire)
04.11.24	OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis (GlobeNewswire)
17.10.24	OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index (GlobeNewswire)
26.09.24	OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update (GlobeNewswire)
10.09.24	OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer (GlobeNewswire)
24.07.24	OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis (GlobeNewswire)
03.07.24	Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 (GlobeNewswire)
01.07.24	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ (GlobeNewswire)
24.06.24	OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies (GlobeNewswire)
20.06.24	OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21) (GlobeNewswire)
19.06.24	OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth (GlobeNewswire)
12.06.24	OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse (GlobeNewswire)
05.06.24	OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant (GlobeNewswire)
30.05.24	OSE Immunotherapeutics Provides Business and Corporate Update (GlobeNewswire)
22.05.24	OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases (GlobeNewswire)
16.04.24	OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective (GlobeNewswire)
10.04.24	OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer (GlobeNewswire)
02.04.24	OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology (GlobeNewswire)
27.03.24	OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update (GlobeNewswire)
27.03.24	OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update (Businesswire)
19.01.24	OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook (Businesswire)
16.10.23	OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors (Businesswire)
27.09.23	OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update (Businesswire)
11.09.23	OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology (Businesswire)
06.07.23	OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: (Businesswire)
04.07.23	OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment (Businesswire)
20.06.23	OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
15.06.23	OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire)
26.05.23	OSE Immunotherapeutics (OSE): Re-initiation Milestones anticipated throughout FY23 (EQS Group)
27.04.23	OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update (Businesswire)
20.04.23	OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology (Businesswire)
18.04.23	OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio (Businesswire)
15.02.23	OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies (Businesswire)
27.05.21	OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer (Businesswire)
16.11.20	OSE IMMUNOTHERAPEUTICS: Trading suspension (Businesswire)
06.12.18	Edison initiates coverage on OSE Immunotherapeutics (OSE) (EQS Group)
28.02.18	OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING® (Businesswire)
04.01.18	OSE Immunotherapeutics to Present at Biotech Showcase™ 2018 Conference (Businesswire)
03.01.18	OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors (Businesswire)
19.12.17	OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases (Businesswire)
14.12.17	OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies (Businesswire)
07.12.17	OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment (Businesswire)
26.10.17	OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE® (Businesswire)
19.10.17	OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy (Businesswire)
02.10.17	OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment (Businesswire)
28.09.17	OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells (Businesswire)
26.09.17	Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs (Businesswire)
26.09.17	Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V